New treatments for chronic myelomonocytic leukemia
Official title: Novel targeted therapies for chronic myelomonocytic leukemia
Funded at Dana-Farber Cancer Inst · NIH-10911848 · Data updated 2026-11-12
This study is looking at chronic myelomonocytic leukemia (CMML) to see how changes in a specific gene affect the disease and how a drug called dasatinib might help treat it, while also figuring out why some patients might not respond to the treatment and what other options could work better together with it.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 2, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $269,244 |
| NIH project number | 5K08CA258803-03 |
| Project ID | NIH-10911848 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with chronic myelomonocytic leukemia who have mutations in the CBL gene.
✕Less likely to help
Patients with CMML who do not have CBL mutations may not benefit from this specific research.
What this research studies
This research focuses on chronic myelomonocytic leukemia (CMML), a serious blood cancer with limited treatment options. It investigates the role of the CBL gene and its mutations in driving the disease, particularly how the LYN kinase contributes to cancer cell growth. The study aims to explore the effectiveness of dasatinib, a drug that inhibits LYN, and to understand how resistance to this treatment develops. Additionally, it seeks to identify other potential therapies that could be combined with dasatinib to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with CBL-mutant CMML.
How similar studies have gone: Previous research has shown promising results with targeted therapies in similar hematologic malignancies, suggesting potential for success in this approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Belizaire, Roger Vincent — Dana-Farber Cancer Inst
- Study coordinator: Belizaire, Roger Vincent
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for a blood cancer called CMML (CBL-mutant CMML)
A physician-scientist is testing targeted drugs to treat a hard-to-kill blood cancer called CMML in patients whose cancer has CBL mutations.
-
Understanding how CMML develops and becomes aggressive
Looks at blocking overactive MEK/ERK signals and BET protein-driven gene activity to slow or reverse aggressive CMML and lower its chance of turning into AML for people whose leukemia has NRAS and ASXL1 mutations.
-
Blocking PLK1 in RAS‑mutated chronic myelomonocytic leukemia
People with relapsed or refractory proliferative CMML that has RAS pathway mutations will receive an oral drug called onvansertib that blocks the cell‑division protein PLK1 to look for safety and early signs of benefit.
-
How inflammation changes blood stem cells and drives progression in chronic myelomonocytic leukemia
Looking at whether inflammation changes blood stem cells and speeds disease in adults with CMML.
-
Patient-based mouse models to find better treatments for chronic myelomonocytic leukemia
Researchers are using mice implanted with patients' CMML cells to try out new treatment approaches for people with chronic myelomonocytic leukemia.
-
Understanding how chronic myelomonocytic leukemia resists targeted therapy
This study is looking at how some people with chronic myelomonocytic leukemia (CMML) might not respond to a treatment called cobimetinib, and it aims to help those patients by figuring out why that happens and finding better ways to treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.